Results from Merck & Co study show 99% effectiveness of elbasvir/grazoprevir for hepatitis C

14 April 2016
merck-700

Findings from a head-to-head study conducted by US pharma Merck & Co (NYSE: MRK) have shown almost complete efficacy of elbasvir/grazoprevir in the treatment of chronic hepatitis C.

A Phase III trial compared the combination to a regimen of sofosbuvir tablets plus peginterferon and ribavirin in both treatment-naïve and treatment-experienced patients with chronic hepatitis C (HCV) genotype 1 or 4 infection.

The efficacy endpoint of sustained virologic response (SVR) 12 weeks after the completion of therapy, SVR12 – considered virologic cure – was achieved in 128 out of 129 of patients receiving elbasvir/grazoprevir for 12 weeks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical